$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025
Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2.
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Equillium Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th.
Opening remarks
During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane Pharma, to define the potential of BAMLET as a drug candidate.